Objectives: Droperidol (DROP) is used in the emergency department (ED) for several indications, but its effect on psychomotor performance is unclear. The purpose of this study was to evaluate the effects of DROP, 2.5 mg intramuscular (IM), on driving performance.
INTRODUCTION
Acute presentations of nausea and vomiting, headache, and agitation all provide frequent therapeutic challenges for the clinician. IM Droperidol (DROP) has been effectively used in the emergency department (ED) setting to treat these complaints [1] [2] [3] [4] [5] . When given IM, DROP's onset of action is from 3 to 10 minutes with a peak effect at 30 minutes. Sedative effects generally last 2 to 4 hours [6] . Therefore, it is likely that a patient will be discharged from a healthcare facility while the sedative effects of DROP persist; this impairment may interfere with the complex psychomotor tasks of driving a car.
The goal of our study was to examine the effect of IM DROP on simulated driving performances. Although many agents must carry warning labels that explain the possible effects on driving or the operating of heavy machinery, no previous study has evaluated the effect of IM DROP on driving performance.
METHODS
We compared the effects of DROP, a neuroleptic butyrophenone tranquilizer, on simulated driving performances [6] . Since the likelihood of driving, after receiving any agent, is greater if the person does not recognize their impairment, we also investigated the subjects' perceptions of drowsiness compared to their actual driving impairment. This study was a randomized, double-blinded, twoperiod, placebo-controlled crossover trial. The Institutional Review Board (IRB) approved the study, and all participants signed a consent form prior to participating in the study. Although this study was approved prior to the FDA Black Box Warning on droperidol, we advised the IRB of this development and a 12-lead EKG pre-screening of all participants was mandated.
Licensed drivers greater than 18 years of age were eligible to participate; pregnancy was an exclusion criterion. All participants were pre-screened with a 12-lead EKG to evaluate QT length. Each volunteer was required to participate in 2 simulations that were scheduled at least 72 hours apart. Each participant was driven to and from the study site by one of the study investigators.
To objectively assess driving in a controlled environment, driving simulators were employed (L-300 Car Simulator System, Doron Precision Systems Inc., Binghamton, NY). The simulators were mounted on a fixed platform and incorporated a typical size steering wheel, gas and brake pedals, seat, and seat belt. Participants had a practice run on the "Destination Driving" course and a test run on the more demanding "Crash Avoidance" course. Both courses tested the participants' abilities to accelerate, brake, steer, and signal in response to images that were projected onto a large screen located in the front of the room. The simulator recorded 50 data points during each of the two driving tests and generated scores based on the number of errors in each of four driving skill areas: acceleration, braking, steering, and signaling. The number of errors was automatically recorded and the final score calculated by comparison to the total number of expected responses. Therefore, the final score represented the total percentage of correct driving responses. Although there is no fixed "passing" or "failing" grade, competent drivers without simulator experience are expected to score approximately 70-75 percent. Driving performance feedback was not provided to the participant by the simulator or by the investigators.
First, participants used the driving simulator for a practice run on the "Destination Driving" course. They were then randomized through a computer-generated random number table to receive either 2.5 mg of IM DROP or an equal volume (1cc) of normal saline (NS). The dosage of DROP is the maximum initial dose recommended by the drug's manufacturer (Taylor Pharmaceuticals, an Akorn Company, Decatur, Illinois) [1] .
In order to assess the subjective effects of DROP versus NS, participants completed a pre-simulator questionnaire 20 minutes after the injection. The five questions were: 1) Do you think you received a placebo or DROP? 2) Rating of drowsiness on a visual analog scale (VAS) 3) Do you feel that your driving will be impaired? 4) Rating of how much you feel your driving will be impaired on VAS 5) Compare your level of impairment to that which you have experienced after consuming alcoholic beverages (0, 1, 2, 3, >3 drinks, or "don't know").
Thirty minutes after the injection, and coincident with the expected peak effects of DROP, participants performed the first test drive. Immediately following the 20-minute simulated drive, participants completed a post-simulator questionnaire that was identical to the pre-simulator questionnaire. At least 72 hours later, the same subjects participated in a second driving simulation. For the second driving simulation, the assignment of DROP, 2.5 mg IM, or normal saline was reversed: (If a subject received DROP, 2.5 mg IM, in the first simulation, the subject received normal saline in the second simulation; conversely, if a subject received normal saline in the first simulation, the subject received DROP, 2.5 mg IM, in the second simulation). Data were analyzed using SAS PROC MIXED. Pearson's chisquare and Fisher's exact test were used to test for significance between binomial parameters. Assuming a 5-point difference on the driving simulator test and a common standard deviation of 2.5, with alpha at 0.05 and power = 0.80, a sample size of 12 was needed. We enrolled 20 paid volunteers to allow for the potential loss of some volunteers.
RESULTS
Twenty qualifying volunteers, 11 men and 9 women, completed the protocol. The mean age was 30 years with a range of 20 to 46 years, and the mean weight was 80 kg. The mean driving experience was 12 years.
As indicated in Table 1 , the participants' subjective impressions of drowsiness and level of impairment (post-injection) were similar before and after the test drive, indicating that the act of simulated driving itself did not change their perception of impairment. Approximately three-quarters of each group correctly identified the solution they had received. Participants receiving DROP rated their drowsiness as significantly greater (38.6 mm +/− 9.0 versus 13.2 mm +/− 9.0, p < .01) than those in the NS group. When receiving DROP, 60% felt that their driving would be impaired, while only 10% (and 0% post simulator) felt that their driving would be impaired after an injection of NS (p = 0.001). This was consistent with the VAS, which confirmed the perception of a much greater level of impairment when receiving DROP (p = 0.0005). Nine of 20 participants (45%) (pre and post simulator) who received DROP compared their expected level of impairment to the equivalent of consuming 2-4 drinks; only one (5%) NS participant (p < .02) compared his expected level of impairment to the equivalent of 2-4 drinks.
There was not a significant difference between the DROP participants and the NS participants in the individual scores for accelerating, braking, steering, and signaling. There was, however, a significant difference between the DROP participants and the NS participants in the overall mean score. The mean driving score with DROP was 68.8% +/− 1.7, and the NS driving score was 73.6% +/− 1.7 (∆ 4.8; p < .015).
DISCUSSION
This study confirms the overall adverse effects (degree of drowsiness) of clinically utilized doses of Droperidol on driving performance. The perception of drowsiness, while driving, may well be of clinical significance. Using a simulator, Weiler, et al. compared the effects of fexofenadine, diphenhydramine, alcohol, and a placebo on driving performance. He found that subjects' perceptions of drowsiness was a weak predictor of accident occurrence, but perceptions of drowsiness did correlate with the inability to maintain a safe minimal following distance, steering instability, and left-lane excursions [7] . Although visual analog scales have been previously used in evaluating drug induced drowsiness and have been shown to correlate with other assessments of sleepiness, the inherent nature of the VAS makes interpretation and statistical analysis of specific VAS values problematic [8, 9] . Given the accepted clinical significance of a 13 mm difference on a VAS assessing pain scale, it is likely that our relatively large VAS difference of more than 25 mm would be meaningful as well as statistically significant [10] .
The deleterious effects of droperidol on driving performance may be relevant to the physician. Prior to the FDA's warning regarding the use of DROP, the drug was commonly used by emergency physicians in the ED for the treatment of vomiting, agitation, and headache [1] [2] [3] [4] [5] . A similar butyrophenone agent, haloperidol, is still commonly used for some of these same indications. Due to their rapid onset and relatively long duration of action, it is likely that patients would be discharged from the ED while still under the influence of these drugs. Because study subjects reported increased perceptions of drowsiness, driving impairment, and intoxication, our data suggests that patients, receiving modest doses of IM DROP, should use caution if they plan to operate a motor vehicle after discharge from a healthcare facility.
LIMITATIONS
There are several limitations to the current study. Although there was a significant difference in the overall mean simulator driving scores, the two groups' mean scores differed by only 4.8 points.
Since there is not a clearly defined failing score, it is not possible to determine whether this decrease in driving ability would actually represent a serious hazard on the road. However, the fact remains that nearly half of the DROP subjects reported impairment comparable to 2-4 alcoholic drinks, and the reported impairment is cause for concern. There are no standardized tests, for our simulator, which would allow for direct comparison with alcohol ingestion, and so we were unable to compare DROP use to alcohol ingestion. It should also be noted that the mean driving experience of our participants is 12 years. It is possible that drivers with less experience may be more significantly affected by DROP. The study subjects were healthy volunteers, unlike many patients who received DROP in the ED for nausea, agitation, or migraine. Such patients might experience greater difficulty with complex psychomotor tasks such as driving. The current study evaluated subjects 30 minutes after an injection of DROP. Most patients would leave an ED at least two hours post injection; the effect of DROP, two hours post injection, was not measured.
CONCLUSION
Participants receiving a commonly utilized dose of droperidol (2.5 mg IM) report increased perceptions of drowsiness, driving impairment, and intoxication. These perceptions were objectively confirmed through the use of simulated driving tests.
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